Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The Company’s lead candidate under development is AL102, an oral once-daily gamma secretase inhibitor (GSI) for desmoid tumors. AL102 has received Fast Track Designation from the U.S. FDA and is currently in the Phase 3 segment of a pivotal study for patients with desmoid tumors (RINGSIDE). The company pipeline also includes AL101, an intravenous GSI, completed Phase 2 for adenoid cystic carcinoma, as well as ADXS-504, a Lm-based therapy for early-stage prostate cancer.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Relations